Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cosmet Dermatol. 2010 Mar;9(1):22-7. doi: 10.1111/j.1473-2165.2010.00480.x.

Sodium L-ascorbyl-2-phosphate 5% lotion for the treatment of acne vulgaris: a randomized, double-blind, controlled trial.

Author information

  • 1University of Miami, Department of Dermatology and Cutaneous Surgery, Cosmetic Medicine and Research Institute, Miami, FL 33140, USA. woolerylloyd@yahoo.com

Abstract

BACKGROUND:

Antioxidants are becoming increasingly important in the treatment of skin disease. In addition to their known anti-inflammatory effects, antioxidants may act to prevent the oxidation of sebum which has been proposed to be comedogenic in acne patients. Sodium L-ascorbyl-2-phosphate (APS) is a stable vitamin C derivative and highly effective antioxidant that has demonstrated efficacy in acne in open label studies.

OBJECTIVE:

To evaluate the efficacy and safety of APS 5% lotion for the treatment of acne in a blinded controlled study.

METHODS:

A total of 50 subjects were randomized in a double-blind controlled trial to receive APS 5% lotion or vehicle for 12 weeks. Evaluation included an Investigator's Global Assessment Score, a Subjects' Global Assessment Score, lesion counts, cutaneous tolerability, and adverse events.

RESULTS:

APS 5% lotion demonstrated statistically significant improvement when compared to vehicle in all of the parameters measured. The adverse event frequency and cutaneous tolerability profile for APS 5% lotion were similar to vehicle.

LIMITATIONS:

Adjunctive topical or oral agents and their impact on acne were not studied in this trial.

CONCLUSIONS:

This study demonstrates that 5% sodium L-ascorbyl-2-phosphate is efficacious as monotherapy for the treatment of acne. APS 5% lotion offers a novel addition to our current acne armamentarium.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center